



**ASSOCIATION BETWEEN IRON DEFICIENCY AND HELICOBACTER PYLORI
INFECTION AMONG SUDANESE PATIENTS IN KHARTOUM STATE – 2018**

Duaa M. A. Elkareem¹, Wafa A. Awad¹, Belal M. Khalil¹, Zeinab S. A. Alsayed², Tarig A. M. Hamid^{1*}

¹Department of Hematology and Immunoematology - Karry University- Khartoum Sudan.

²Department of Hematology and Immunoematology – Sharq Elnile College – Khartoum Sudan.

*Corresponding Author: Tarig A. M. Hamid

Department of Hematology and Immunoematology - Karry University- Khartoum Sudan.

Article Received on 03/05/2018

Article Revised on 24/05/2018

Article Accepted on 14/06/2018

ABSTRACT

Helicobacter pylori (*H. Pylori*) are a Gram-negative spirally shaped bacterium. Infection rates are strongly related to poor living conditions; also iron deficiency (ID) is most common nutritional deficiency that associated with poverty. A case-control study was conducted in the Military hospital, Khartoum state, Sudan, where *H. pylori* infection was diagnosed. Study done during January to April 2018. A total of one hundred and two participants were included, among them 51 with *H. pylori* infection as a case group, and 51 normal individuals as control group. Venous blood samples were collected from each subject; serum was separated for measurement of iron level. The present study showed that There was a significant decrease of s. iron level among case group with a mean (69.6, 98.1 µg/dL) of case to control group respectively, (P; 0.00). Also show there is no correlation between s. iron level compare with gender, *H. pylori* infection duration, treatment and other disease with p value (0.11, 0.34, 0.32, 0.58) respectively. Present study concluded that *Helicobacter pylori* has a significant effect on serum iron level and *H. pylori* infection is a cause of iron deficiency. Indicate there is an association between iron deficiency and *H. pylori* infection.

KEYWORDS: Iron deficiency anemia, serum Iron, helicobacter Pylori infection.

1. INTRODUCTION

Iron deficiency is estimated to be the most common nutritional deficiency in the world, the most common cause of anemia (Iron deficiency anemia) and represent a major public health problem, affects 500–600 million people globally, especially in developing country. *Helicobacter pylori* (*H. Pylori*) are a Gram-negative spirally shaped bacterium. It is strictly micro Europhilic requires carbon dioxide and rich growth media. Infection rates are strongly related to poor living conditions and overcrowding during childhood (Risk factors). Infection is presumed to an individual through the oral –oral or, possibly, fecal –oral route, and has been suggested to be mostly interfamilial [Kroot JJ *et al*; (2011)].

The path physiologic mechanisms by which *H. pylori* is associated with the development of iron deficiency (ID) and iron deficiency anemia (IDA) are not fully understood, and more questions than answers remain. It is still not known why some patients manifest this association and why in other patients it is not present, or there are other associations; or why some of the infections are asymptomatic [Correa *et al*; 2001]. However the eradication of this pathogen not only led to increase in response to oral iron therapy and level of ferritin but also could cure anemia completely in several

cases with unexplained IDA [David G (2005), Hunt RH (1998), Kroot JJ (2011); *et al*]. Over the past decade, it has been linked *H. pylori* and ID development with a recently discovered hormone called Hcpidin [park *et al*; 2011]. This hormone is produced in the liver and regulates iron metabolism in enterocyte and decrease the releasing of stored iron from macrophages of the reticule endothelial system [Kroot *et al*; 2009]. Hcpidin rises after *H. pylori* infection, acting as an acute phase reactant in response to the inflammation produced in the gastric mucosa, resulting in pathology known as “anemia of inflammation or chronic disease [cherian *et al*; 2008]. Preliminary studies show that serum hcpidin is elevated in patients infected with *H. pylori* [Ozkasap *et al*; 2003]. And these levels are normalized after eradication of the infection allowing the iron to be absorbed by the enterocytes and released from macrophages of the reticule endothelial system, where they are confined [Azab *et al*; (2013)].

Other possible causes of iron imbalance in patients infected with *H. pylori* are chronic gastritis, which occurs in all individuals infected with *H. pylori*. This can cause bleeding when it becomes erosive gastritis [Yip *et al*; 1997]. Especially in patients with active bleeding peptic ulcer and in patients who chronically ingest non-

steroidal anti-inflammatory drug including aspirin [Song *et al.*; 2013]. Reduced iron absorption as a result of elevated pH of gastric juice has also been attributed to *H. pylori*. The present study was planned to observe whether *H. pylori* infection in the gastric mucosa is responsible for iron deficiency, so as early detection and eradication of *H. pylori* can prevent the development of complications as gastritis, gastric, duodenal ulcer and consequence iron deficiency.

2. MATERIAL AND METHODS

2.1 Study area and population: This case-control study was conducted in the Military hospital, Khartoum state, Sudan, where *H. pylori* infection was diagnosed. Study done during January to April 2018 and included 102 samples, 51 of these samples were collected from patient diagnosed with *H. pylori* as a case group, and 51 samples were collected from apparently healthy person as control group.

2.2 Sample collection: A total of 3 ml venous blood samples were collected by using sterile disposable syringes and poured into plain containers, immediately centrifuged to obtain serum which separated and stored at 2-8 C°. Serum used for estimation of serum iron level spectrophotometry among two studied group. Standard stored at 2-30 C°.

2.3 Statistical Analysis All values were expressed as mean \pm SD. Statistical analyses were done using the Student's t-test to assess differences among study groups. The level of significance was set at $P < 0.05$.

3. RESULTS

The study has been done on 102 participants, 51 from patient with *H. pylori* include 35 female, 16 male as a case group and 51 apparent healthy individual, 35 female and 16 male as control group.

Table 1: Demographic data of two studied group.

	Case Mean \pm SD	Control Mean \pm SD	p. value
age	27.1 \pm 9.3	32.3 \pm 14.6	0.033

The mean of age among two studied group were found (27.1, 32.3) ($P < 0.03$) among cases and control group respectively.

Table 2: Comparison of means and SD of serum iron level among the two studied group.

	Case Mean \pm SD	Control Mean \pm SD	p. value
s. iron level	69.6 \pm 23.5	98.1 \pm 31.5	0.000

There was a significant decrease of s. iron level among case group with a mean of case to control group (69.6, 98.1 $\mu\text{g/dL}$) ($P < 0.00$).




Figure (1): frequency and percentage of patient with disease other than *H. pylori* infection among case population.

There were 8% of case group has another infection rather than *H. pylori* infection




Figure (2): frequency and percentages of *H. pylori* patient who took a treatment among case population.

There were 16.7% of *H. pylori* patient whose took an *H. pylori* treatment among case group.

Table 3: Correlation between S. iron level and gender, *H. pylori* infection duration, treatment and persistence of other disease among case group.

	Gender	Duration	Other disease	Treatment
P. Value	0.119	0.340	0.580	0.329

There is no association between s. iron level compare with gender, *H. pylori* infection duration, treatment and other disease with p value (0.11, 0.34, 0.32, 0.58) respectively.

4. DISCUSSION

One hundred and tow blood samples were included in the present study, 51 from patient with *H. pylori* as case group and 51 from healthy individual as control group.

Present study show significant decreased of serum iron in case group with a mean (69.6 ± 23.5) than control group (98.1 ± 31.5 $\mu\text{g/dL}$) (P; 0.00), that agree with other studies, study done by (Durdi, *et al.* 2011) in Shahid Beheshti Hospital of Babol University of Medical Sciences showed significant association between *H. pylori* infections and anemia (P; 0.04), and study done by (Durdi Qujeq *etal.*, 2011) was conducted in Shahid Beheshti Hospital of Babol University of Medical Sciences, Babol, Iran from August 2007 to July 2008. The study group consisted of 35 patients with *H. pylori* and healthy subjects as the control group, the serum iron in *H. pylori* positive group was lower than in the control group (89.67 ± 31.26 vs. 110.92 ± 28.45 $\mu\text{g/dL}$) (P; 0.04). Means that *H. pylori* infection in the gastric mucosa is responsible for iron deficiency.

Our study disagrees with previous study done by (Tayyibe, *et al.* 2014) to investigate the association between iron deficiency anemia and *H. Pylori* in patients with normal gastrointestinal tract endoscopy results, which conclude that there was no association between iron deficiency and *H. pylori*. In present study 27% of cases exhibited significant decrease of serum iron while 73% of them within normal level of serum iron, mean that not all *H. pylori* infected patient have an ID, this may influence by confounding factors and may have a relation with genetic susceptibility.

Present study show there is no association between s. iron level compare with gender, *H. pylori* infection duration, treatment and other disease with p value (0.11, 0.34, 0.32, 0.58) respectively.

5. CONCLUSION

It is concluded that *Helicobacter pylori* has a significant effect on serum iron level and *H. pylori* infection is a cause of iron deficiency.

Indicate there is an association between iron deficiency and *H. pylori* infection.

ACKNOWLEDGEMENT

We would like to express deepest gratitude to Al Doctor Centre for medical training Khartoum Sudan.

REFERENCES

- Lee GR. *Iron deficiency and iron-deficiency anemia*. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, Eds. *Wintrobe's Clinical Hematology*, Vol 1. Baltimore: Williams & Wilkins, 1999; 979-1010.
- De Maeyer E, Adiels-Tegman M. The prevalence of anaemia in the world. *World Health Statistics Quarterly - Rapport Trimestrielle Statistiques Sanitaires Mondiales*, 1985; 38: 302-16.
- Annibale B, Capurso G, Lahner E, Passi S, Ricci R, *et al.* Concomitant alterations in intragastric pH and ascorbic acid concentrations in patients with *Helicobacter pylori* gastritis and associated iron deficiency anaemia. *Gut*, 2003; 52: 496– 501.
- Windle HJ, Kelleher D, Crabtree JE. Childhood *Helicobacter pylori* infection and growth impairment in developing countries: a vicious cycle? *Pediatrics*, 2007; 119: E754–759.

- Roubaud Baudron C, Franceschi F, Salles N, Gasbarrini A. Extragastric diseases and *Helicobacter pylori*. *Helicobacter*, 2013; 18: 44-51.
- Hudak L, Jaraisy A, Haj S, Muhsen K. An updated systematic review and meta-analysis on the association between *Helicobacter pylori* infection and iron deficiency anemia. *Helicobacter*, 2017; 22. doi: 10.1111/hel.12330
- Franceschi F, Tortora A, Gasbarrini G, Gasbarrini A. *Helicobacter pylori* and extragastric diseases. *Helicobacter*, 2014; 19: 52-8.
- Azab SF, Esh AM. Serum hepcidin levels in *Helicobacter pylori* infected children with iron-deficiency anemia: a case-control study. *Ann Hematol*, 2013; 92: 1477-1483.
- Cherian S, Forbes DA, Cook AG, Sanfihippo FM, Kemna EH, Swinkels DW, Burgner DP. An insight into the relationships between hepcidin, anemia, infections and inflammatory cytokines in pediatric refugees: a cross-sectional study. *PLoS one*, 2008; 3: e4030.
- Correa P Gastric cancer: overview. *Gastroenterol Clin North Am*, 2013; 42: 211-217.
- David G, MikeB, RichardS, Will L. *medical microbiology*. 18th ed Churchill livingstone, 2005; 309-310.
- Hunt RH, Thompson ABR. Canadian *Helicobacter pylori* Consensus Conference. *Can J Gastroenterol*, 1998; 12(1): 31-41.
- Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. *Clin Chem*, 2011; 57: 1650-1669.
- Ozkasap S, Yarali N, Isik P, Bay A, Kara A, Tunc B. The role of prohepcidin in anemia due to *Helicobacter pylori* infections. *Pediatr Hematol Oncol*, 2013; 30: 425-431.
- Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem*, 2001; 276: 7806-7810.
- Rajesh B, Rattan Lalchhpujani. *Essentials of Medical Microbiology* 3th ed Jaypee brothers, 2011; 313.
- Song HJ, Kwon JW, Kim N, Park YS. Cost Effectiveness Associated with *Helicobacter pylori* Screening and Eradication in Patients Taking No steroidal Anti-Inflammatory Drugs and/or Aspirin. *Gut Liver*, 2013; 7: 182-189 27.
- Yip R, Limburg PJ, Ahiquist DA, Carpenter HA, O'Neill A, Kruse D, Stitham S, Gold BD, Gunter EW, Looker AC, Par-kinson AJ, Nobmann ED, Petersen KM, Ellefson M, Schwartz S. Pervasive occult gastrointestinal bleeding in an Alaska native population with prevalent iron deficiency. Role of *Helicobacter pylori* gastritis. *JAMA*, 1997; 27: 1135-1139.